Maintenance Notice (10:30 PM January 4 - 8:00 AM January 5, 2025 UTC): This website is scheduled to be unavailable due to maintenance. We appreciate your patience and understanding.
Published TCIMAIL newest issue No.197 | Notice of Discontinuing the Use of Password-Protected Compressed Files | Various analytical charts can be searched on each product detail page and Product Document Search (The kinds of analytical charts differ by product)
Maximum quantity allowed is 999
请选择数量
CAS RN: 191732-72-6 | 產品號碼: L0332
| 產品號碼 | L0332 |
| 純度/分析方法 | >98.0%(HPLC) |
| 分子式 / 分子量 | C__1__3H__1__3N__3O__3 = 259.27 |
| 外觀與形狀（20°C） | Solid |
| 儲存條件 | Refrigerated (0-10°C) |
| 應避免的情況 | Heat Sensitive |
| 包裝和容器 | 1G-Glass Bottle with Plastic Insert （閲覽圖片）, 250MG-Glass Bottle with Plastic Insert （閲覽圖片） |
| CAS RN | 191732-72-6 |
| MDL編號 | MFCD07772307 |
產品規格
| Appearance | White to Orange to Green powder to crystal |
| Purity(HPLC) | min. 98.0 area% |
| Purity(Nonaqueous Titration) | min. 95.0 % |
性質
| 熔點 | 271 °C |
| 水溶性 | Insoluble |
| Degree of solubility in water | 0.3 g/l |
| 溶解性（不溶於） | Ethanol |
GHS
| 圖形表示 |
|
| 信號詞 | Danger |
| 危險性說明 | H360 : May damage fertility or the unborn child. |
| 防範說明 | P501 : Dispose of contents/ container to an approved waste disposal plant. P202 : Do not handle until all safety precautions have been read and understood. P201 : Obtain special instructions before use. P280 : Wear protective gloves/ protective clothing/ eye protection/ face protection. P308 + P313 : IF exposed or concerned: Get medical advice/ attention. P405 : Store locked up. |
相關法規
| RTECS # | TW7342160 |
運輸資料
| HS編碼* | 2933.79-000 |
Application
Lenalidomide: An Immunomodulatory Agent with Antiangiogenic and Antineoplastic Properties
Lenalidomide (CC-5013), a more potent thalidomide [T2524] analogue such as pomalidomide [P2074], is an immunomodulatory agent with antiangiogenic and antineoplastic properties. It is reported that lenalidomide inhibits proliferation and induces apoptosis of certain hematopoietic tumor cells including multiple myeloma, mantle cell lymphoma, and myelodysplastic syndromes in vitro. Immunomodulatory properties of lenalidomide include activation of T cells and natural killer (NK) cells, increased numbers of NKT cells, and inhibition of pro-inflammatory cytokines (e.g., TNF-α and IL-6) by monocytes. (The product is for research purpose only.)
References
- Dexamethasone Synergizes with Lenalidomide to Inhibit Multiple Myeloma Tumor Growth, But Reduces Lenalidomide-Induced Immunomodulation of T and NK Cell Function
- Molecular mechanism of action of immune-modulatory drugs thalidomide, lenalidomide and pomalidomide in multiple myeloma (a review)
- Development and validation of LC-MS/MS method for the quantitation of lenalidomide in human plasma using Box-Behnken experimental design
- Simultaneous quantification of lenalidomide, ibrutinib and its active metabolite PCI-45227 in rat plasma by LC-MS/MS: Application to a pharmacokinetic study
文章/手冊
TCIMail
產品文件 （部分產品的分析圖譜無法提供，敬請諒解。）
SDS
請選擇語言。
請求的SDS不可用。
如需更多幫助，請聯繫我們 。
產品規格
檢驗報告(CoA)及其他文檔
請輸入批號
輸入的批號不正確
示例 CoA
可下載CoA示例。注：該示例可能非最新批次的CoA。
目前沒有該產品的 CoA 示例。
分析圖譜
請輸入批號
輸入的批號不正確
很抱歉，您搜索的分析圖譜無法提供。